Statement of problem
Various factors are responsible for sleep bruxism; however, whether the dopaminergic agonist group of drugs is effective in the treatment of sleep bruxism is unclear.
The purpose of this systematic review was to evaluate the effect of the dopaminergic agonist group of drugs in controlling sleep bruxism in comparison with no treatment or placebo-controlled treatment.
Material and methods
Two electronic databases, PubMed and Cochrane Central, were searched by using the keywords bruxism, sleep bruxism, dopamine, and dopamine agonist. After screening titles and abstracts, only those articles which met predefined inclusion criteria were selected for full-text assessment. Clinical trials using the dopaminergic agonist group of drugs as a treatment approach to sleep bruxism were included.
The literature search yielded a total of 64 articles from the 2 electronic databases (PubMed, 53; Cochrane Central, 11). After removal of the duplicates (n=8), the initial screening of titles and abstracts was performed by 2 independent reviewers, removing 46 articles. A total of 10 articles were selected for full-text reading, and 4 studies were included for qualitative analysis.
Levodopa (L-DOPA) and Bromocriptine showed decrease in root mean square value in electromyography per bruxism burst (P<.001) and 20% to 30% reduction of bruxism episodes during sleep in 2 different studies. However, treatment with bromocriptine led to conflicting result in another study in terms of frequency of bruxism episodes and amplitude of muscle contractions in electromyography (EMG). Bruxism bursts and episodes were also not significantly improved with another dopaminergic agonist group of drugs, Pramipexole (P>.001). Based on the limited evidence and conflicting results, significant conclusions cannot be generated, and further studies are required.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Prosthetic Dentistry
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- International Classification of Sleep Disorders.(Online version)3rd ed. American Academy of Sleep Disorders, Darien, IL2014
- International consensus on the assessment of bruxism: report of a work in progress.J Oral Rehabil. 2018; 45: 837-844
- The Glossary of Prosthodontic Terms: Ninth Edition.J Prosthet Dent. 2017; 117: e1-e105
- Orofacial pain: guidelines for assessment, diagnosis, and management.6th ed. Quintessence Publishing Co, Inc, Chicago, IL2018: 229
- Bruxism physiology and pathology: An overview for clinicians.J Oral Rehabil. 2008; 35: 476-494
- Pharmacotherapy for sleep bruxism.Cochrane Database Syst Rev. 2007; 4: CD005514
- Classification of sleep disorders.Neurotherapeutics. 2012; 9: 687-701
- A critical evaluation of occlusal therapy. Occlusal adjustment procedures.J Am Dent Assoc. 1985; 110: 743-750
- Lack of associations between occlusal and cephalometric measures, side imbalance in striatal D2 receptor binding, and sleep-related oromotor activities.J Orofac Pain. 2001; 15: 64-71
- Bruxism is mainly regulated centrally, not peripherally.J Oral Rehabil. 2001; 28: 1085-1091
- Nocturnal masseter muscle activity and urinary catecholamine levels in bruxers.J Dent Res. 1980; 59: 1571-1576
- Urinary levels of catecholamines among individuals with and without sleep bruxism.Sleep Breath. 2009; 13: 85-88
- Sleep bruxism: Current knowledge and contemporary management.J Conserv Dent. 2016; 19: 383-389
- Neurobiological mechanisms involved in sleep bruxism.Crit Rev Oral Biol Med. 2003; 14: 30-46
- Respiratory related recruitment of the masseter: Response to hypercapnia and loading.J. Appl. Physiol. 1991; 70: 2508-2513
- The relationship between sleep bruxism and obstructive sleep apnea based on polysomnographic findings.J Clin Med. 2019; 8: 1653
- Associations of reported bruxism with insomnia and insufficient sleep symptoms among media personnel with or without irregular shift work.Head Face Med. 2008; 4: 4
- Time-linked concurrence of sleep bruxism, periodic limb movements, and EEG arousals in sleep bruxers and healthy controls.Clin Oral Investig. 2013; 18: 507-513
- Restless legs syndrome and sleep bruxism: prevalence and association among Canadians.Sleep. 1994; 17: 739-743
- Genesis of sleep bruxism: Motor and autonomic-cardiac interactions.Arch Oral Biol. 2007; 52: 381-384
- Enhanced sympathetic cardiac modulation in bruxism patients.Clin Auton Res. 2006; 16: 276-280
- Advances in studying phasic dopamine signaling in brain reward mechanisms.Front Biosci. 2013; 5: 982-999
- Alternative pathways for catecholamine action in oral motor control.Neurosci Lett. 2005; 386: 34-39
- Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum.Psychopharmacology. 1988; 95: 556-559
- The functional anatomy of basal ganglia disorders.Trends Neurosci. 1989; 12: 366-375
- Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology.Yale J Biol Med. 2016; 89: 37-47
- Comparative review of dopamine receptor agonists in Parkinson's disease.CNS Drugs. 1996; 5: 369-388
- An algorithm for the management of restless legs syndrome.Mayo Clin Proc. 2004; 79: 916-922
- Single nucleotide polymorphisms in genes of dopaminergic pathways are associated with bruxism.Clin Oral Investig. 2018; 22: 331-337
- Genetic polymorphisms in the serotonergic system are associated with circadian manifestations of bruxism.J Oral Rehabil. 2016; 43: 805-812
- Association of genetic, psychological and behavioral factors with sleep bruxism in a Japanese population.J Sleep Res. 2012; 21: 289-296
- DNA is hypomethylated in circadian manifestations of bruxism.Oral Dis. 2018; 24: 1132-1139
- The effect of the catecholamine precursor L-DOPA on sleep bruxism: a controlled clinical trial.Mov Disord. 1997; 12: 73-78
- Effects of the D2 receptor agonist bromocriptine on sleep bruxism: report of two single-patient clinical trials.J Dent Res. 1997; 76: 1610-1614
- A randomised, open-label, crossover study of the dopamine agonist, pramipexole, in patients with sleep bruxism.J Sleep Res. 2017; 26: 64-72
- Double-blind, crossover, placebo-controlled trial of bromocriptine in patients with sleep bruxism.Clin Neuropharmacol. 2001; 24: 145-149
- Current treatments of bruxism.Curr Treat Options Neurol. 2016; 18: 6-10
- CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials.Lancet. 2001; 357: 1191-1194
- The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.BMJ. 2011; 343: d5928
- Buspirone as an antidote to SSRI-induced bruxism in 4 cases.J Clin Psychiatry. 1999; 60: 857-860
- Signs of bruxism and temporomandibular disorders among psychiatric patients.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 103: 60-63
- Effects of pergolide on severe sleep bruxism in a patient experiencing oral implant failure.J Oral Rehabil. 2007; 34: 317-322
- Fluoxetine-induced sleep bruxism in an adolescent treated with buspirone: a case report.Spec Care Dentist. 2009; 29: 215-217
- Relationship between non-functional masticatory activity and central dopamine in stressed rats.J Oral Rehabil. 2010; 37: 827-833
- Psychotropic drugs and bruxism.Expert Opin Drug Saf. 2014; 13: 1319-1326
- How to use the evidence: assessment and application of scientific evidence.(Available at:)https://www.nhmrc.gov.au/sites/default/files/documents/reports/clinical%20guidelines/how-to-use-evidence-cp69.pdfDate accessed: July 7, 2020
Published online: January 14, 2021
© 2020 by the Editorial Council for the Journal of Prosthetic Dentistry.